The fish oil-based medication known as omega-3 carboxylic acids or omega-3 CA did not decrease the risk of cardiac events compared to a placebo, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2020. The virtual meeting is Friday, November 13-Tuesday, November 17, 2020, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide.
Fish oil supplements containing the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) are commonly taken to prevent or reduce complications of heart disease.
A 2017 American Heart Association Science Advisory noted that omega-3 fish oil supplements prescribed by a health care professional may help prevent death from heart disease in patients who recently…
